Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K.M. Akkerhuis is active.

Publication


Featured researches published by K.M. Akkerhuis.


Journal of Hypertension | 2011

A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals

Jasper J. Brugts; Aaron Isaacs; M.P.M. de Maat; E. Boersma; C. M. van Duijn; K.M. Akkerhuis; A.G. Uitterlinden; J. C. M. Witteman; François Cambien; Claudio Ceconi; Willem J. Remme; Michel E. Bertrand; Toshiharu Ninomiya; Stephen B. Harrap; John Chalmers; Stephen MacMahon; Kim Fox; Roberto Ferrari; M. L. Simoons; A. J. Danser

Aims To investigate whether genetic variation in the renin–angiotensin–aldosterone system (RAAS) and kallikrein-bradykinin pathways is related to hypertension and blood pressure (BP) response to angiotensin-converting enzyme (ACE) inhibitor therapy in stable coronary artery disease (CAD) patients. Methods and results In 8907 stable CAD patients from the EUROPA trial, 52 haplotype-tagging single-nucleotide polymorphisms (SNPs) in 12 candidate genes within the RAAS and kallikrein-bradykinin pathways were investigated for association with hypertension (defined as BP ≥160/95 mmHg or use of antihypertensives) and BP response to ACE inhibitors, during a 4-week run-in period. All analyses were adjusted for age, sex, body mass index and creatinine clearance and corrected for multiple testing. Results Hypertension was present in 28.3% of the patients (n = 2526); median BP reduction after perindopril was 10/4 mmHg. Four polymorphisms, located in the ACE (rs4291), angiotensinogen (rs5049) and (pro)renin receptor (rs2968915; rs5981008) genes were significantly associated with hypertension in two vascular disease populations of CAD (EUROPA) and cerebrovascular disease (PROGRESS; n = 3571). A cumulative profile demonstrated a stepwise increase in the prevalence of hypertension, mounting to a 2–3-fold increase (P for trend <0.001). Similar associations on hypertension were observed for angiotensinogen in a healthy population (n = 2197). In addition, genetic polymorphisms were identified that significantly modified the BP reduction by ACE inhibitor therapy; however, the observed BP differences were small and did not remain significant after permutation analysis. Conclusion This large genetic association study identified genetic determinants of hypertension in three cohorts of patients with vascular disease and healthy individuals.


Thrombosis and Haemostasis | 2014

Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study.

Michelle A.H. Sonneveld; Jin Ming Cheng; Rohit M. Oemrawsingh; M.P.M. de Maat; Isabella Kardys; Hector M. Garcia-Garcia; R.-J. van Geuns; E. Regar; Patrick W. Serruys; E. Boersma; K.M. Akkerhuis; F. W. G. Leebeek

High von Willebrand factor (VWF) plasma levels are associated with an increased risk of coronary artery disease. It has been suggested that the increase of VWF levels is partly due to endothelial dysfunction and atherosclerosis. Our aim was to investigate the association between coronary plaque burden, the presence of high-risk coronary lesions as measured by intravascular ultrasound virtual histology (IVUS-VH) and VWF levels. In addition, we studied the association between VWF levels and one-year cardiovascular outcome. Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery was performed in 581 patients undergoing coronary angiography for acute coronary syndrome (ACS) (n= 318) or stable angina pectoris (SAP) (n= 263). Arterial blood was sampled prior to the coronary angiography. VWF antigen (VWF:Ag) levels were measured using ELISA (n= 577). Patients with ACS had significantly higher VWF:Ag levels than SAP patients (median 1.73 IU/ml [IQR 1.27-2.31] vs 1.26 IU/ml [0.93-1.63], p< 0.001). High coronary plaque burden was associated with higher VWF:Ag levels (β= 0.12, p=0.027) in SAP patients, but not in ACS patients. In ACS patients, VWF:Ag levels were associated with 1-year MACE (HR 4.14 per SD increase of lnVWF:Ag, 95 % CI 1.47-11.6), whereas in SAP patients VWF:Ag levels predicted 1-year all-cause death and hospitalisation for ACS (HR 7.07 95 % CI 1.40-35.6). In conclusion, coronary plaque burden was associated with VWF:Ag levels in SAP patients undergoing coronary angiography. In ACS and SAP patients, high VWF levels are predictive of adverse cardiovascular outcome and death during one-year follow-up.


European Heart Journal | 2004

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes

Matthew T. Roe; Kenneth W. Mahaffey; Rakhi Kilaru; John H. Alexander; K.M. Akkerhuis; M. L. Simoons; Robert A. Harrington; Barbara E. Tardiff; Christopher B. Granger; Erik Magnus Ohman; David J. Moliterno; A. M. Lincoff; Paul W. Armstrong; F. Van de Werf; Robert M. Califf; Eric J. Topol


European Heart Journal | 2001

Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events Meta-analysis of three studies involving 995 patients

K.M. Akkerhuis; Peter Klootwijk; W. Lindeboom; Victor A. Umans; Simon Meij; P.-P. Kint; M. L. Simoons


European Heart Journal | 2000

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.

K.M. Akkerhuis; J. W. Deckers; E. Boersma; Robert A. Harrington; Janina Stępińska; Kenneth W. Mahaffey; Robert G. Wilcox; A. M. Lincoff; Matyas Keltai; Eric J. Topol; Robert M. Califf; M. L. Simoons


European Heart Journal | 2002

Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.

Eelko Ronner; E. Boersma; K.M. Akkerhuis; Robert A. Harrington; A. M. Lincoff; J. W. Deckers; Karl R. Karsch; N. S. Kleiman; A. Vahanian; Eric J. Topol; Robert M. Califf; Maarten L. Simoons


Journal of Electrocardiology | 2000

Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.

K.M. Akkerhuis; Arthur Maas; Klootwijk Pa; Mitchell W. Krucoff; Simon Meij; Robert M. Califf; M. L. Simoons


Netherlands Heart Journal | 2017

In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment

N. van Boven; K.M. Akkerhuis; Sharda S. Anroedh; Linda C. Battes; Kadir Caliskan; W. Yassi; Olivier C. Manintveld; Jan-Hein Cornel; Alina A. Constantinescu; H. Boersma; Victor A. Umans; Isabella Kardys


European Heart Journal | 2013

Near-infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease

Rohit M. Oemrawsingh; Jin Ming Cheng; Hector M. Garcia-Garcia; R.J.M. van Geuns; Eveline Regar; Isabella Kardys; Mattie J. Lenzen; P. W. Serruys; K.M. Akkerhuis; E. Boersma


The Journal of Clinical Endocrinology and Metabolism | 2018

Response to Letter: Cardiometabolic biomarkers and their temporal patterns predict poor outcome in chronic heart failure (Bio-SHiFT study).

Milos Brankovic; K.M. Akkerhuis; Umans; E. Boersma; Isabella Kardys

Collaboration


Dive into the K.M. Akkerhuis's collaboration.

Top Co-Authors

Avatar

E. Boersma

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Isabella Kardys

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Rohit M. Oemrawsingh

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Victor A. Umans

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. L. Simoons

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

R.J.M. van Geuns

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

P. W. Serruys

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

E. Regar

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge